Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chloroquine + docetaxel
- Development stage
- Phase 2
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Chloroquine + docetaxel is a combination therapy consisting of the antimalarial and autophagy inhibitor chloroquine and the taxane-class chemotherapeutic agent docetaxel. This combination is being investigated primarily for its potential to overcome multidrug resistance (MDR) in cancer cells, particularly in advanced or metastatic breast cancer. Chloroquine inhibits autophagy—a survival mechanism that can allow cancer cells to resist chemotherapy—thereby sensitizing tumor cells to the cytotoxic effects of docetaxel. Docetaxel stabilizes microtubules, preventing cell division and promoting apoptosis in rapidly dividing tumor cells. Preclinical studies have shown that co-delivery of these agents enhances anticancer efficacy compared to either drug alone, especially against resistant cancer cell lines[1][4]. Clinical trials have demonstrated promising objective response rates with manageable toxicity profiles when this combination is used after failure of anthracycline-based chemotherapy[5].
- Other names
- chloroquine and docetaxelCQ + DTX
02
Targets
NeuraminidaseTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on chloroquine + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chloroquine + docetaxel.